Personal information

Websites & social links

https://mmct.univie.ac.at
University of Vienna profile page

Other IDs

Scopus Author ID: 7003987375
Scopus Author ID: 7003987375
SciProfiles: 1647432

Keywords

gene delivery, gene therapy, cancer immune therapy, nanoparticles

Countries

Austria

Activities

Collapse all

Employment (4)

University of Vienna: Wien, AT

Employment
Source: check_circle
University of Vienna - u:cris

Universität Wien: Vienna, AT

2013 to present | Professor for Pharmaceutical Sciences
Employment
Source: Self-asserted source
Manfred Ogris

Ludwig-Maximilians-Universität München: München, Bayern, DE

2001 to 2013 | Research group leader
Employment
Source: Self-asserted source
Manfred Ogris

CRC Institute for Cancer Research: Birmingham, England, GB

1999 to 2001 | PostDoc
Employment
Source: Self-asserted source
Manfred Ogris

Education and qualifications (3)

Ludwig-Maximilians-Universität München: München, Bayern, DE

2001 to 2009 | Privatdozent
Qualification
Source: Self-asserted source
Manfred Ogris

University of Natural Resources and Life Sciences, Vienna (BOKU) : Vienna, AT

1996 to 1999 | Dr.rer.nat.techn.
Education
Source: Self-asserted source
Manfred Ogris

University of Natural Resources and Life Sciences: Vienna, AT

1989 to 1996 | Dipl. Ing.
Education
Source: Self-asserted source
Manfred Ogris

Peer review (24 reviews for 16 publications/grants)

Review activity for ACS applied materials & interfaces. (3)
Review activity for ACS nano. (2)
Review activity for Advanced functional materials. (1)
Review activity for Advanced healthcare materials (1)
Review activity for Advanced materials. (2)
Review activity for Advanced science. (1)
Review activity for Advanced therapeutics. (1)
Review activity for Biomacromolecules. (1)
Review activity for Cancer gene therapy. (1)
Review activity for Communications medicine. (1)
Review activity for Journal of controlled release. (1)
Review activity for Molecular biology reports. (1)
Review activity for Molecular pharmaceutics. (2)
Review activity for Molecular therapy (1)
Review activity for Molecular therapy. (2)
Review activity for Small. (3)
How many people are using ORCID?